- Conditions
- Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor, Metastatic Cancer, WNT Pathway, HCC, Desmoid, Microsatellite Stable Colorectal Cancer, Metastatic Castration-resistant Prostate Cancer, Familial Adenomatous Polyposis (FAP), Endometrial Carcinoma, Prostate Cancer, Microsatellite Instability-High Colorectal Cancer, Adamantinomatous Craniopharyngioma
- Interventions
- FOG-001, mFOLFOX-6, Nivolumab, Trifluridine/tipiracil, Bevacizumab
- Drug
- Lead sponsor
- Parabilis Medicines, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 619 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 25 more
Institution Directory
Clinical trials at Massachusetts General Hospital
Sites in Boston, MA
Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
1489
Shown on this page
12
Current sort
Recently updated
Campus scope
Massachusetts General Hospital, Boston, MA
Additional filters apply within this campus.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 157–168 of 1,489 matching trials with a site at Massachusetts General Hospital, Boston, MA.
Live ClinicalTrials.gov results.
Live official records
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT05579366
Status at this site: Recruiting
- Conditions
- High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer, Cervical Cancer
- Interventions
- Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin, Itraconazole
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 952 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more
Digital Coach to Support Exposure Therapy Homework for Anxious Youth
NCT07666672
Site status not listed — check the official record
- Conditions
- Anxiety Disorders, OCD
- Interventions
- BraveBot, Self-Guided Exposure Therapy Homework
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 12 Years to 22 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027
- U.S. locations
- 3
- States / cities
- Belmont, Massachusetts • Boston, Massachusetts • Cambridge, Massachusetts
Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma
NCT03224767
Site status not listed — check the official record
- Conditions
- BRAF V600E Mutation Present, Papillary Craniopharyngioma
- Interventions
- Vemurafenib, Cobimetinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 106
- States / cities
- Birmingham, Alabama • Auburn, California • Berkeley, California + 85 more
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
NCT02886065
Site status not listed — check the official record
- Conditions
- Smoldering Multiple Myeloma
- Interventions
- Hiltonol, Citarinostat, Lenalidomide, PVX-410
- Drug · Biological
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • New York, New York • Durham, North Carolina + 1 more
Boston Lung Cancer Study (Molecular and Genetic Analysis of Lung Cancer)
NCT03029325
Status at this site: Recruiting
- Conditions
- Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease
NCT05205954
Status at this site: Recruiting
- Conditions
- Cirrhosis, End Stage Liver DIsease, Liver Cirrhosis, Liver Disease Chronic
- Interventions
- Hepatology Home Hospital
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Molecular Epidemiology of Acute Respiratory Distress Syndrome (ARDS)
NCT00006496
Site status not listed — check the official record
- Conditions
- Acute Respiratory Distress Syndrome, Lung Diseases
- Interventions
- Not listed
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 4,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Malignant Brain Tumor, Glioma, Coping Skills
- Interventions
- Information and Support Intervention, Usual supportive care
- Behavioral · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Family Members at INcreased-risk for Developing Inflammatory Bowel Disease
NCT06655415
Status at this site: Recruiting
- Conditions
- Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), IBD-unclassified (IBD-U), Indeterminate Colitis, Crohn's Disease Colon, Crohn's Colitis, Crohn's Ileocolitis, Crohn's Gastritis, Crohn's Jejunitis, Crohn's Duodenitis, Crohn's Esophagitis, Ulcerative Proctitis, Ulcerative Proctosigmoiditis
- Interventions
- Not listed
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 14 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2034
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
NCT01472094
Site status not listed — check the official record
- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2027
- U.S. locations
- 17
- States / cities
- Duarte, California • New Haven, Connecticut • Chicago, Illinois + 12 more
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
NCT05998330
Status at this site: Recruiting
- Conditions
- Liver Disease Chronic, End Stage Liver DIsease, Cirrhosis, Cirrhosis, Liver, Advanced Cirrhosis
- Interventions
- LiverPAL
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
About this Massachusetts General Hospital institution page
- What this page lists
- ClinicalTrials.gov records that list Massachusetts General Hospital in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
- Site status
- A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.
Related: all institution pages, trials led by Massachusetts General Hospital at any site, browse by condition, or browse by U.S. city.